FROM HOPE TRIAL TO ONTARGET TRIAL: THE «HOPE» TO REACH THE «TARGET» - TO IMPROVE PROGNOSIS IN HIGH RISK PATIENTS

Abstract

Results of HOPE trial are analyzed. It is noted, that treatment with angiotensine converting enzyme inhibitor (iACE) ramipril improves the prognosis in high risk cardio-vascular patients. The objectives and study design of ONTARGET/TRANSCEND trials are introduced. Perspectives of joint use of ACE inhibitor and antagonist of angiotensin II receptor are discussed.

Keywords

• high cardio-vascular risk
• ramipril
• telmisartan
• норе trial
• ontarget trial